AstraZeneca US Diabetes Launch Delayed

19.10.2015 - AstraZeneca’s US launch of a fixed-dose diabetes drug combination of saxagliptin and dapagliflozin has been delayed, due to concerns of the Food and Drug Administration (FDA). In a...